Stat News
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
S
Source
Stat News
Read full article at Stat News
Opens original article in a new tab
Advertisement



